Mifepristone-eribulin combination clinically active in triple-negative breast cancer

[News]

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.

More... (http://www.news-medical.net/news/20150515/Mifepristone-eribulin-combination-clinically-active-in-triple-negative-breast-cancer-patients.aspx)